Clinical Trials Logo

Diabetes Mellitus, Type 2 clinical trials

View clinical trials related to Diabetes Mellitus, Type 2.

Filter by:

NCT ID: NCT02454153 Completed - Diabetes Clinical Trials

Hyperglycemic Profiles in Obstructive Sleep Apnea: Effects of PAP Therapy

HYPNOS
Start date: December 2014
Phase: N/A
Study type: Interventional

This is a randomized control trial in people with diabetes and obstructive sleep apnea who will be randomly assigned for 3 months to PAP therapy along with healthy lifestyle and sleep education or healthy lifestyle and sleep education.

NCT ID: NCT02453685 Completed - Clinical trials for Diabetes Mellitus, Type 2

A Study to Compare Insulin Intensification of Biphasic Insulin Aspart 30 and Insulin Analogues (Insulin Glargine and Insulin Aspart) in Insulin naïve Type 2 Diabetic Patients

Start date: August 31, 2015
Phase: Phase 4
Study type: Interventional

This trial is conducted globally. The aim of this trial is to compare stepwise insulin intensification of biphasic insulin aspart (BIAsp) 30 and basal-bolus therapy with insulin glargine and insulin aspart in insulin naïve type 2 diabetic patients inadequately controlled on oral anti-diabetic therapy.

NCT ID: NCT02453555 Completed - Clinical trials for Diabetes Mellitus, Type 2

Empagliflozin Add on to Linagliptin Study in Japanese Patient With Type 2 Diabetes Mellitus

Start date: May 14, 2015
Phase: Phase 3
Study type: Interventional

This trial will compare the use of fixed dose combination of empagliflozin and linagliptin to linagliptin alone in patient with type 2 diabetes mellitus

NCT ID: NCT02451722 Completed - Clinical trials for Diabetes Mellitus Type 2

Evaluation of Pressure Distribution of Kyboot Shoes in Comparison to Other Foot Wear

Kyboot
Start date: May 2015
Phase: N/A
Study type: Interventional

Comparison and evaluation of pressure distribution, gait pattern, changes in the movement of the center of pressure, shock absorbing capabilities and comfort of wear using KyBoot shoes versus normal foot wear in diabetic and healthy subjects.

NCT ID: NCT02451137 Completed - Clinical trials for Diabetes Mellitus, Type 2

A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)

Start date: June 16, 2015
Phase: Phase 4
Study type: Interventional

Primary Objective: Demonstrate clinical benefit of Toujeo in achieving individualized Healthcare Effectiveness Data and Information Set (HEDIS) glycated hemoglobin (HbA1c) targets (<8% if age >=65 years or with defined comorbidities or otherwise <7%) at 6 months without documented symptomatic (Blood Glucose <=70 mg/deciliter [mg/dL]) and/or severe hypoglycemia at any time of day from baseline to 6 months in uncontrolled insulin naive participants with type 2 diabetes initiating basal insulin therapy in a real world setting. Secondary Objectives: Compare Toujeo to other commercially available basal insulins at 6 months after initiating insulin therapy in a real world setting in terms of: - Participant persistence with assigned basal insulin therapy. - Risk of hypoglycemia including the incidence and rate of documented symptomatic and severe hypoglycemia. - Changes in HbA1c, fasting plasma glucose, body weight - Differences in participant and provider- reported outcomes (including Diabetes Treatment Satisfaction Questionnaire Status and Change Versions (DTSQs) and (DTSQc), Hypoglycemia Patient Questionnaire, and participant and provider reported Global Effectiveness Scale (GES). - Healthcare resource utilization including hospitalizations and emergency department or other provider visits and healthcare costs.

NCT ID: NCT02450097 Completed - Obesity Clinical Trials

Metabolic and Hormonal Effects of 5:2 Intermittent Fasting

Start date: December 2013
Phase: N/A
Study type: Interventional

The aim of the present study is to investigate in subjects with and without type 2 diabetes the effect of calorie restriction (CR) according to the 5:2 method for 6 months (every week two days caloric fasting with 500 calories for women and 600 calories for men and five days of normal caloric intake) on risk markers for cardiovascular disease and certain cancers (hyperinsulinemia, insulin resistance, IGF-1, IGFBP-1, IGFBP-2, glucose, HbA1c, blood lipids, markers of inflammation and oxidative stress) and on peptides regulating glucose metabolism and appetite as well as the effect on blood pressure, body composition, waist- and hip- circumference. DNA will also be analysed at the start and after 6 months to investigate any epigenetic effects. After completed study there will be a follow up after additional 6 months.

NCT ID: NCT02449213 Completed - Clinical trials for Diabetes Mellitus, Type 2

A Biobehavioral Model of Diabetes Risk in Chinese Immigrants

Start date: March 11, 2016
Phase:
Study type: Observational

This prospective, longitudinal study of Chinese American immigrants will examine whether psychosocial factors (e.g., acculturative stress, social isolation, discrimination) are associated with markers of type 2 diabetes risk over time, and whether such associations are mediated by inflammatory pathways.

NCT ID: NCT02449187 Completed - Diabetes Clinical Trials

Investigate the Effect of Food on the Pharmacokinetics of JLP-1310 in Healthy Male Volunteers

Start date: August 2, 2017
Phase: Phase 1
Study type: Interventional

A randomized, open-label, single dose, crossover study to investigate the effect of food on the pharmacokinetics of JLP-1310 in healthy male volunteers.

NCT ID: NCT02448498 Completed - Diabetes Mellitus Clinical Trials

Strength Training Regimen for Normal Weight Diabetics

STRONG-D
Start date: February 2016
Phase: N/A
Study type: Interventional

The Strength Training Regimen in Normal Weight Diabetics (STRONG-D) study will examine the effectiveness of different exercise regimen types in controlling diabetes for the normal weight type 2 diabetes population.

NCT ID: NCT02445911 Completed - Clinical trials for Diabetes Mellitus, Type 2

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of KQ-791 in Diabetes Mellitus

Start date: June 2015
Phase: Phase 1
Study type: Interventional

This study will consist of multiple ascending oral doses in up to 3 groups, for 29 days.